Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Common Equity: 2009-2012

Historic Common Equity for Lexicon Pharmaceuticals (LXRX) over the last 4 years, with Sep 2012 value amounting to $252.8 million.

  • Lexicon Pharmaceuticals' Common Equity rose 49.14% to $252.8 million in Q3 2012 from the same period last year, while for Sep 2012 it was $252.8 million, marking a year-over-year increase of 49.14%. This contributed to the annual value of $297.6 million for FY2011, which is 20.46% up from last year.
  • As of Q3 2012, Lexicon Pharmaceuticals' Common Equity stood at $252.8 million, which was up 3.21% from $244.9 million recorded in Q2 2012.
  • Lexicon Pharmaceuticals' 5-year Common Equity high stood at $733.9 million for Q4 2009, and its period low was $129.9 million during Q3 2009.
  • Over the past 3 years, Lexicon Pharmaceuticals' median Common Equity value was $252.8 million (recorded in 2012), while the average stood at $252.5 million.
  • Data for Lexicon Pharmaceuticals' Common Equity shows a peak YoY increase of 106.97% (in 2010) and a maximum YoY decrease of 66.34% (in 2010) over the last 5 years.
  • Over the past 4 years, Lexicon Pharmaceuticals' Common Equity (Quarterly) stood at $733.9 million in 2009, then slumped by 66.34% to $247.0 million in 2010, then increased by 20.46% to $297.6 million in 2011, then skyrocketed by 49.14% to $252.8 million in 2012.
  • Its last three reported values are $252.8 million in Q3 2012, $244.9 million for Q2 2012, and $269.0 million during Q1 2012.